Linical Co (TSE:2183) EBIT: 円-2,994 Mil (TTM As of Mar. 2026)


TSE:2183 Linical Co Ltd TSE:2183
48 GF Score
Price 円202.00
GF Value 円310.47
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Linical Co EBIT?

Linical Co TSE:2183 -0.98% 48 EBIT is 円-2,994 Mil as of Mar. 2026. GuruFocus rates TSE:2183 with a GF Score™ of 48/100 and a GF Value™ of 円310.47 (Possible Value Trap). The stock has 5 warning signs investors should review.

Linical Co's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was 円-2,461 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-2,994 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Linical Co's annualized ROC % for the quarter that ended in Mar. 2026 was -30.81%. Linical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,425.77%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Linical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -186.11%.

Linical Co  (TSE:2183) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Linical Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-3124.03 * ( 1 - 2.78% )/( (10199.007 + 9516.466)/ 2 )
=-3037.181966/9857.7365
=-30.81 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14420.708 - 903.897 - ( 5400.488 - max(0, 6524.858 - 9842.662+5400.488))
=10199.007

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11999.633 - 530.486 - ( 5204.281 - max(0, 6382.494 - 8335.175+5204.281))
=9516.466

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Linical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-4921.05/( ( (370.424 + max(-1082.676, 0)) + (319.879 + max(-1901.592, 0)) )/ 2 )
=-4921.05/( ( 370.424 + 319.879 )/ 2 )
=-4921.05/345.1515
=-1,425.77 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2525.622 + 0 + 1916.552) - (903.897 + 0 + 4620.953)
=-1082.676

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1738.933 + 0 + 1391.961) - (530.486 + 0 + 4502)
=-1901.592

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Linical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-2993.536/1608.493
=-186.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Linical Co EBIT Related Terms

Linical Co EBIT Historical Data

* Premium members only.

The historical data trend for Linical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Linical Co EBIT Chart

Linical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,046.12 1,391.44 677.87 -496.04 -2,993.54

Linical Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 294.45 -231.33 -264.71 -533.01 -2,460.53

TSE:2183 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Linical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Linical Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Linical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Linical Co's EV-to-EBIT falls into.


TSE:2183
48GF Score
Linical Co Ltd TSE:2183
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Linical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円-2,994 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円-2,994 Mil mean?
Linical Co (TSE:2183) has a EBIT of 円-2,994 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Linical Co.
Is Linical Co's EBIT too high?
Linical Co's current EBIT is 円-2,994 Mil. Overall, Linical Co has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Linical Co's EBIT compare to VRTX and REGN?
Linical Co's EBIT of 円-2,994 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Linical Co. Linical Co's current EBIT is 円-2,994 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Linical Co stock overvalued right now?
Based on GuruFocus' analysis, Linical Co (TSE:2183) is currently considered Possible Value Trap. The stock's GF Value™ is 円310.47, compared to a current price of 円202.00 — trading 34.9% below its estimated fair value. The current EBIT is 円-2,994 Mil. Linical Co's overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Linical Co (TSE:2183), the current EBIT is 円-2,994 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Linical Co (TSE:2183) Overvalued in 2026?

Based on GuruFocus' analysis, Linical Co stock appears to be undervalued. The current stock price of 円202.00 is trading 34.9% below its estimated GF Value™ of 円310.47. GuruFocus considers Linical Co to be Possible Value Trap.

Key valuation signals for TSE:2183:

  • EBIT: 円-2,994 Mil
  • GF Value™: 円310.47 vs. price of 円202.00 (34.9% below fair value)
  • GF Score™: 48/100 with 5 warning signs

No single metric tells the full story. See the TSE:2183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Linical Co Business Description

Address 1-6-1 Miyahara, 10th floor, Shin-Osaka Brick Building, Yodogawa-ku, Osaka, JPN, 532-0003
Linical Co Ltd is a pharmaceutical company.
48GF Score

Get the complete analysis for TSE:2183

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円202.00
Price
円310.47
GF Value